Login to Your Account

Clinic Roundup

Wednesday, April 3, 2013
• Axelar AB, of Stockholm, Sweden, part of the Karolinska Development AB portfolio, reported preliminary interim results from its Phase II study of AXL1717, indicating that the small-molecule IGF-1 receptor inhibitor is effective in treating patients with non-small-cell lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription